RenovoRx, Inc.
- RNXT
- NASDAQ
- Biotechnology
- Oncology Biotech
- Drug-Device Combo
$1.16
Today +1.75%Quote Oct 19, 2026, 08:00 PM UTC
−31.36%over the last month
Max drawdown −34.1%From 1-month high −31.8%3 months +32.2%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About RenovoRx
RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
17
Market value
$52.4M
Quote Oct 19
Floor
$1.09
5.8% below price
Resistance
$1.18
2.0% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about RNXTPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free